University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Translational Research Institute

TRI Study of the Month

Larry Johnson, M.D. (right), is assisted on the study by TRI’s Faryal Jalbani, M.D., MSPH, regulatory affairs specialist II (left) and Monica Smith, B.A., CRS, TRI Regulatory Affairs manager.
Larry Johnson, M.D. (right), is assisted on the study by TRI’s Faryal Jalbani, M.D., MSPH, regulatory affairs specialist II (left) and Monica Smith, B.A., CRS, TRI Regulatory Affairs manager.

UAMS Principal Investigator: Larry Johnson, M.D., professor, College of Medicine Department of Internal Medicine; director, Division of Pulmonary and Critical Care Medicine; director, Adult Cystic Fibrosis Program

Summary: A Phase 1b/2a, multicenter study to evaluate nebulized bacteriophage treatment for adults with cystic fibrosis with chronic pseudomonas aeruginosa (PsA) pulmonary infection. The study will determine if the new drug candidate, BX004-A, which contains three bacteriophages, is safe to inhale.

Significance: BX004-A could potentially help patients with chronic PsA lung infections by reducing the amount of PsA in the lung.

TRI Services: Medicare coverage analysis, study budget development, regulatory support, administration of Clinical Trial Management System, and post-award financial management.

Sponsor: BiomX Inc.